

DAOA (rs2391191) Report

By Dan Purser MD

The DAOA (D-amino acid oxidase activator, also known as G72) gene variant rs2391191 (Arg30Lys) is a nonsynonymous missense polymorphism that fundamentally alters glutamatergic neurotransmission by modulating D-serine breakdown and NMDA receptor function.

Biological Mechanism

- **D-Serine Depletion:** The DAOA gene regulates the enzyme D-amino acid oxidase (DAAO), which degrades D-serine—the primary co-agonist required to open NMDA receptors in the prefrontal cortex and hippocampus.
- **NMDA Receptor Hypofunction:** Variant alleles alter DAOA expression, leading to hyperactivation of DAAO and reduced synaptic D-serine levels, driving cortical NMDA hypofunction and impaired neuroplasticity.

Associated Diseases

- **Schizophrenia & Schizoaffective Disorder:** Strongly linked to disease susceptibility, particularly negative symptoms and cognitive deficits.
- **Bipolar Disorder (Types I & II):** Associated with mood instability, cognitive manic features, and psychotic depression.
- **Major Depressive Disorder (MDD):** Implicated in treatment-resistant depression driven by glutamatergic signaling deficits.
- **Early-Onset Alzheimer's Disease:** Acts as a genetic modifier, influencing the age of symptom onset and rate of cognitive decline.

Clinical Symptoms & Endophenotypes

- **Visuospatial Deficits:** Reduced performance on spatial reasoning and visual-motor integration tasks (e.g., block design performance).
- **Cognitive Manic Symptoms:** Marked susceptibility to racing thoughts, severe distractibility, and speech disorganization during manic or hypomanic states.

- **Prefrontal Executive Dysfunction:** Impairments in working memory, cognitive flexibility, and processing speed.
- **White Matter Microstructural Changes:** Lower fractional anisotropy (reduced white matter integrity) in the corpus callosum and frontotemporal tracts.

Long-Term Complications

- **Blunted Long-Term Potentiation (LTP):** Chronic deficit in synaptic plasticity, leading to progressive cognitive fatigue and memory consolidation failure.
- **Accelerated White Matter Degradation:** Long-term disruption of frontostriatal and interhemispheric neural connectivity.
- **Monoaminergic Treatment Resistance:** Poor responsiveness to standard SSRIs or typical antipsychotics that fail to address upstream NMDA co-agonist depletion.

Pharmaceutical Interventions

- **Sodium Benzoate:** A direct DAAO inhibitor that prevents D-serine breakdown, significantly improving cognitive, positive, and negative symptoms in schizophrenia and bipolar trials.
- **Exogenous NMDA Co-Agonists (D-Serine / D-Cycloserine):** Pharmacological administration of D-serine to directly saturate the NMDA glycine/serine binding site.
- **GlyT1 Inhibitors (e.g., Iclepertin):** Blocks glycine reuptake in synaptic clefts to enhance NMDA receptor co-activation and compensate for D-serine loss.
- **Pro-Glutamatergic Antipsychotics:** Atypical agents (such as Clozapine, Lurasidone, or Cariprazine) that enhance prefrontal glutamatergic output or D-serine availability.

Natural & Nutraceutical Support

- **Sarcosine (N-Methylglycine):** A natural GlyT1 inhibitor that elevates synaptic glycine levels, restoring NMDA receptor throughput.

- **N-Acetylcysteine (NAC, 1,200–2,000 mg/day):** Modulates the cystine-glutamate antiporter to normalize extracellular glutamate levels and buffer against cortical oxidative stress.
- **High-Dose EPA/DHA Omega-3s:** Preserves white matter microstructural integrity and reduces neuroinflammatory suppression of NMDA transmission.
- **Active B-Complex (B6, B9, B12):** Essential cofactors for serine hydroxymethyltransferase, supporting endogenous D-serine synthesis and one-carbon metabolism.
- **Ginkgo Biloba & Ashwagandha:** Botanical neuroprotectants that support prefrontal microcirculation, enhance synaptic plasticity, and protect against glutamatergic excitotoxicity.